Pancreatic Adenoma

Pancreatic adenoma” isn’t a standard modern diagnosis. Most of the time, people are referring to one of two benign (non-cancer) pancreatic tumors: (1) serous cystadenoma, a watery, honeycomb-like cystic growth that is almost always benign; or (2) an islet-cell (neuroendocrine) tumor such as an insulin-secreting tumor (insulinoma), which is often small and usually benign. Today, doctors and pathologists prefer precise names like “serous cystadenoma,” “mucinous cystic neoplasm,” “IPMN,” or “pancreatic neuroendocrine tumor (NET).” RadiopaediaNCBI+2NCBI+2PubMed Central

Other names

You may hear these instead of “pancreatic adenoma”: serous cystadenoma (also called microcystic or honeycomb cyst), mucinous cystic neoplasm (older term “mucinous cystadenoma”), intraductal papillary mucinous neoplasm (IPMN), or pancreatic neuroendocrine tumor (NET) such as insulinoma (formerly “islet-cell adenoma”). In inherited conditions like von Hippel-Lindau (VHL) or MEN1, the pancreas may develop multiple cysts or NETs. Using these specific names helps guide testing, follow-up, and treatment. PubMed Central+1Gastro JournalNCBI

Types

1. Serous cystadenoma (SCA). A benign, watery, microcystic mass, often with a “honeycomb” look and sometimes a central scar. Subtypes include microcystic (classic), oligocystic/macrocystic, and solid variants. Usually incidental. RadiopaediaNCBI

2. Mucinous cystic neoplasm (MCN). Historically called “mucinous cystadenoma,” now termed MCN because a small fraction can transform; occurs mostly in middle-aged women and has ovarian-type stroma. PubMed Central

3. Intraductal papillary mucinous neoplasm (IPMN). A mucin-producing duct lesion (main-duct, branch-duct, or mixed). Risk and management follow guideline criteria. PubMed CentralScienceDirect

4. Pancreatic neuroendocrine tumors (NETs). Often small and slow-growing; may be functioning (insulinoma, gastrinoma, glucagonoma, VIPoma, etc.) or non-functioning. “Islet-cell adenoma” is an older term—insulinoma remains the classic benign example. NCBIStatPearls

5. Syndromic forms. In VHL, multiple serous cysts/SCAs and NETs occur; in MEN1, multiple NETs (including insulinoma) can occur. Gastro JournalNCBI

Causes and risk factors

Note: true “causes” are often unknown; below are well-described associations and risk factors that raise the chance of these benign pancreatic tumors.

1. Age. Many cystic lesions (including SCAs and IPMNs) are found more often after age 50.

2. Female sex (MCN). MCN typically affects women due to its ovarian-type stroma. PubMed Central

3. Von Hippel-Lindau (VHL). Strongly linked with multiple pancreatic cysts, serous cystadenomas, and NETs. Gastro Journal

4. Multiple Endocrine Neoplasia type 1 (MEN1). Linked with pancreatic NETs, including insulinoma (about 5–10%). NCBI

5. Family history of pancreatic cysts or NETs. Familial clustering occurs in VHL/MEN1 families. gutnliver.org

6. Chronic pancreatic duct changes. Ductal blockage/inflammation may favor cyst formation in some lesions (e.g., branch-duct IPMN). PubMed Central

7. Hormonal milieu. MCN biology is influenced by ovarian-type stroma (estrogen/progesterone receptors). PubMed Central

8. Germline tumor-suppressor gene changes. Loss of VHL function drives pancreatic cystogenesis in VHL. BioMed Central

9. MEN1 gene mutations. Predispose to multiple endocrine tumors including pancreatic NETs. Medscape

10. Prior abdominal imaging (detection bias). More scans → more incidental small cysts.

11. Long-standing diabetes (association, not cause). NETs and cysts are found more often in people who undergo frequent imaging for metabolic issues.

12. Metabolic stress on islets. In insulinoma, clonal islet-cell overgrowth can arise sporadically without a clear trigger. NCBI

13. Smoking (general pancreatic risk). Increases risk for several pancreatic lesions; may co-exist with cystic disease picked up on scans.

14. Obesity (general abdominal imaging/NAFLD workups). More imaging leads to more incidental cyst discovery.

15. Chronic pancreatitis (background changes). Can complicate imaging and favor duct irregularity (important when judging IPMN). PubMed Central

16. Cyst wall/epithelial genetic alterations. MCN/IPMN have distinct molecular features guiding risk. PubMed Central

17. Somatostatin-receptor biology (NETs). Drives both imaging uptake and, in some cases, growth behavior. Journal of Nuclear Medicine

18. Pregnancy (rare MCN growth). Hormonal shifts can enlarge mucinous lesions; observation is individualized (reported in case series).

19. Prior abdominal surgery/trauma (rare). Can reveal or complicate cysts seen later.

20. Unknown/idiopathic. Most SCAs and sporadic insulinomas have no clear external cause. NCBI+1

Symptoms

1. No symptoms at all. Most serous cystadenomas are found by accident on a scan. NCBI

2. Dull upper-abdominal ache. From stretching of the pancreas or nearby tissues.

3. Fullness or pressure. A larger cyst can press on the stomach or intestines.

4. Early fullness after small meals. Due to mass effect near the stomach.

5. Nausea or mild vomiting. If the stomach outlet or duodenum is nudged.

6. Back pain. Pain can radiate backward from the pancreas’ retroperitoneal location.

7. Jaundice (yellow eyes/skin). A head-of-pancreas cyst can compress the bile duct.

8. Itchy skin and dark urine. Sometimes accompany jaundice.

9. Intermittent pancreatitis-like pain. Certain duct-involving lesions (e.g., IPMN) can trigger inflammation. PubMed Central

10. Unplanned weight loss. From poor intake and nausea when large cysts cause symptoms.

11. Insulinoma “lows” (hypoglycemia). Sweating, tremor, palpitations, hunger during fasting or exertion. NCBI

12. Confusion or behavior change with hypoglycemia. The brain needs glucose (neuroglycopenic symptoms). NCBI

13. Blurred or double vision during a “low.” A typical neuroglycopenic symptom in insulinoma. Medscape

14. Seizures or loss of consciousness (severe lows). An emergency sign with insulinoma. NCBI

15. Ulcers/heartburn or diarrhea (gastrinoma/VIPoma, less common). Functioning NETs can cause hormone-related symptoms.

Diagnostic tests

A) Physical exam (bedside clues)

1. General exam and vitals. Many people look well; fever suggests inflammation; weight loss may be noted.

2. Eye/skin check for jaundice or scratch marks. Suggests bile-duct blockage and itching from a head-of-pancreas mass.

3. Abdominal palpation. A very large, superficial cyst may be palpable, but most are too deep to feel.

4. Neurologic check during a “low.” Confusion, slurred speech, or unsteadiness point to hypoglycemia in insulinoma. NCBI

B) Manual/bedside assessments (simple in-clinic tests)

5. Point-of-care glucose during symptoms. A finger-stick showing low glucose with symptoms suggests insulinoma; relief after glucose supports Whipple’s triad. NCBI

6. Serial symptom diary (timing vs meals/fasting). Helps distinguish fasting hypoglycemia (insulinoma) from post-meal lows (other causes).

7. Abdominal tenderness mapping. Gentle and deep palpation localize epigastric discomfort and guide imaging urgency.

8. Nutritional status check. Weight/BMI and muscle mass trends document impact of chronic symptoms.

C) Lab & pathological tests

9. Comprehensive metabolic panel and liver tests. Elevated bilirubin/alkaline phosphatase with jaundice suggests bile-duct compression by a head lesion.

10. Serum amylase/lipase. Useful if pancreatitis-like pain occurs; not specific for cysts.

11. 72-hour supervised fast with glucose, insulin, C-peptide, proinsulin and sulfonylurea screen. Gold-standard biochemical test for insulinoma when safe and indicated. NCBI

12. Chromogranin A (NET marker). A general NET biomarker; interpretation depends on proton-pump inhibitors and renal function.

13. EUS-FNA cyst fluid CEA. CEA ≥~192–200 ng/mL favors a mucinous cyst (e.g., MCN or IPMN) over a serous cyst. It does not prove cancer. PubMed Central+1

14. EUS-FNA cyst fluid glucose. Low intracystic glucose (≈30–50 mg/dL) strongly favors mucinous cysts and often outperforms CEA for this question. GIE JournalPubMed CentralMDPI

15. Cytology and molecular testing of cyst fluid. Looks for mucinous epithelium and mutations that help classify cyst type; complements imaging and chemistry. Frontiers

D) Electrodiagnostic/monitoring tests (used when endocrine symptoms are suspected)

16. Continuous glucose monitoring (CGM). Tracks glucose patterns to document spontaneous hypoglycemic episodes in daily life; supports work-up for insulinoma.

17. ECG during symptomatic lows. Hypoglycemia can provoke palpitations/arrhythmias; ECG documents rhythm changes in severe episodes.

18. EEG if seizures/confusion are unexplained. Helps confirm that events during hypoglycemia are neuroglycopenic rather than primary epilepsy.

E) Imaging tests

19. Pancreas-protocol CT or MRI/MRCP. First-line imaging to see cyst features (size, location, septations, central scar) and relation to the ducts. SCAs often show microcysts and sometimes a stellate scar (“honeycomb”). Radiopaedia

20. Endoscopic ultrasound (EUS) ± FNA. Offers high-resolution images right next to the pancreas and allows safe sampling of cyst fluid for CEA/glucose/cytology when criteria are met. Frontiers

21. Somatostatin-receptor PET/CT (e.g., 68Ga-DOTATATE). Best-in-class functional scan for neuroendocrine tumors; detects small/occult NETs better than older octreotide scans and often changes management. PubMed CentralJournal of Nuclear Medicine

22. Contrast-enhanced ultrasound (selected centers). Can help characterize vascularity of cyst walls/solid components when MRI is equivocal.

23. ERCP (selected IPMN cases). Endoscopic contrast into the pancreatic duct helps if there’s suspected main-duct involvement; now used sparingly due to risks—EUS is often preferred. PubMed Central

Non-Pharmacological Treatments

1. Diaphragmatic breathing
   Description: Slow belly breathing 10–15 minutes, 2–3 times daily.
   Purpose: Reduce pain-related muscle tension and nausea.
   Mechanism: Activates the vagus nerve and parasympathetic system, lowering cortisol and visceral pain signaling.
   Benefits: Less pain flare, better appetite, calmer digestion.

2. Gentle trunk mobility (cat-camel, side bends)
   Purpose: Ease abdominal wall guarding and back tightness.
   Mechanism: Improves thoracolumbar fascia glide; reduces nociceptive input.
   Benefits: More comfortable posture, better sleep.

3. Walking program (graded)
   Purpose: Maintain fitness and bowel motility.
   Mechanism: Stimulates peristalsis, anti-inflammatory myokines.
   Benefits: Less bloating, improved energy, weight stability.

4. Core activation (low-load)
   Purpose: Support posture without straining the abdomen.
   Mechanism: Engages transversus abdominis/pelvic floor to reduce mechanical pain.
   Benefits: Better tolerance of daily tasks.

5. Gentle yoga (restorative poses)
   Purpose: Calm autonomic arousal; help sleep.
   Mechanism: Mind-body down-regulation, improved flexibility.
   Benefits: Fewer pain spikes, improved well-being.

6. Heat therapy (warm packs)
   Purpose: Relax muscle spasm around the upper abdomen/back.
   Mechanism: Vasodilation and decreased muscle spindle activity.
   Benefits: Short-term pain relief.

7. Positioning for comfort (left lateral, knees flexed)
   Purpose: Reduce pancreatic/peritoneal stretch pain.
   Mechanism: Lowers traction on retroperitoneal structures.
   Benefits: Less nausea/pain after meals.

8. Pelvic and thoracic manual stretching
   Purpose: Improve rib/pelvic movement to reduce referred pain.
   Mechanism: Fascia and intercostal lengthening.
   Benefits: Easier deep breathing.

9. Gentle myofascial release (trained therapist)
   Purpose: Reduce trigger points from chronic guarding.
   Mechanism: Normalizes tissue tone, decreases peripheral sensitization.
   Benefits: Lower baseline pain.

10. TENS (transcutaneous electrical nerve stimulation)
    Purpose: Non-drug analgesia.
    Mechanism: Gate control and endorphin release.
    Benefits: Short-term pain relief at home.

11. Sleep hygiene plan
    Purpose: Restore circadian rhythm for healing.
    Mechanism: Improves GH/melatonin; reduces pain sensitivity.
    Benefits: Better energy and appetite.

12. Small-frequent-meal coaching
    Purpose: Ease fullness and improve nutrient intake.
    Mechanism: Reduces gastric distension; improves fat absorption with enzymes.
    Benefits: Weight stability, fewer symptoms.

13. Dietitian-guided fat management
    Purpose: Limit greasy stools; ensure vitamins A/D/E/K.
    Mechanism: Tailors fat grams and MCT oil use.
    Benefits: Less steatorrhea, better nutrition.

14. Fluid and electrolyte plan
    Purpose: Prevent dehydration with vomiting/diarrhea.
    Mechanism: Scheduled oral rehydration, sodium/potassium balance.
    Benefits: Reduced fatigue, safer meds.

15. Prehabilitation before surgery (if planned)
    Purpose: Improve outcomes and shorten recovery.
    Mechanism: Aerobic/strength training, nutrition, and breathing exercises.
    Benefits: Fewer complications.

Mind-Body / “Gene-Environment” & Educational 

16. Pain neuroscience education — explains how pain amplifies; reduces fear-avoidance → better activity.

17. Guided imagery/relaxation — lowers sympathetic drive; may reduce nausea and pain perception.

18. Mindfulness (10–20 min/day) — improves coping, lowers stress hormones that can worsen symptoms.

19. CBT-based coping skills — reframes catastrophic thoughts; supports adherence to surveillance.

20. Medication literacy session — how/when to take enzymes, PPIs, antiemetics; prevents errors.

21. Nutrition label training — practical skills to find hidden fats/simple sugars.

22. Return-to-work pacing — graded exposure to tasks; prevents overexertion flares.

23. Family education — what symptoms matter, how to help with meals and appointments.

24. Alcohol- and smoke-cessation counseling — lowers pancreatitis risk; supports healing.

25. Vaccination counseling (flu, pneumonia, hepatitis as appropriate) — prevents infections that can complicate care.

---

Drug Treatments

These medicines do not “treat” the adenoma itself; they treat symptoms or complications. Typical adult doses are examples; your clinician will tailor them to you.

1. Acetaminophen (Paracetamol) — Analgesic/antipyretic. Usual: 500–1000 mg up to 3–4×/day (max 3–4 g/day depending on liver status). Purpose: baseline pain control. Mechanism: central COX modulation. Side effects: liver toxicity at high doses or with alcohol.

2. NSAIDs (e.g., Ibuprofen 200–400 mg 3×/day; Naproxen 250–500 mg 2×/day) — Class: NSAID. Purpose: inflammatory pain. Mechanism: COX inhibition. Side effects: stomach/renal/cardiovascular risks; avoid in ulcers/CKD.

3. Tramadol (25–50 mg q6–8h PRN) — Class: weak opioid/SNRI. Purpose: moderate breakthrough pain. Side effects: nausea, dizziness, dependence, serotonin syndrome risk with SSRIs.

4. Short-course opioids (e.g., morphine/oxycodone as directed) — for severe pain not controlled otherwise; risks: constipation, dependence, sedation—use sparingly with close oversight.

5. Pancreatic Enzyme Replacement Therapy (PERT; e.g., lipase units 25–50k with meals) — Class: digestive enzymes. Purpose: steatorrhea/weight loss. Mechanism: replaces lipase/other enzymes. Side effects: constipation, mouth irritation if chewed.

6. Proton Pump Inhibitors (e.g., omeprazole 20–40 mg/day) — Purpose: decrease acid, reduce enzyme inactivation, ease dyspepsia. Side effects: headache, low magnesium with long use.

7. Antiemetics (ondansetron 4–8 mg q8–12h PRN) — Class: 5-HT3 antagonist. Purpose: nausea control. Side effects: constipation, QT prolongation risk.

8. Prokinetic (metoclopramide 5–10 mg before meals/bed) — Purpose: early satiety/gastroparesis-like symptoms. Side effects: drowsiness, rare tardive dyskinesia; use short term.

9. Bile acid sequestrant (cholestyramine 4 g 1–2×/day) — Purpose: pruritus from cholestasis. Mechanism: binds bile acids. Side effects: constipation, drug interactions; separate from other meds.

10. Ursodeoxycholic acid (10–15 mg/kg/day split doses) — Purpose: cholestatic itch/enzymes; consult specialist. Side effects: diarrhea, rare liver issues.

11. Antibiotics (e.g., piperacillin–tazobactam IV per protocol) — Purpose: infected pancreatic cyst (rare). Side effects: allergy, diarrhea; culture-guided therapy.

12. Insulin or oral diabetes meds — chosen based on glucose profile if diabetes develops; purpose: glycemic control to protect nutrition and healing.

13. Vitamin supplementation (A, D, E, K; B12; folate) — Purpose: correct fat-soluble and other deficiencies in malabsorption. Doses based on labs.

14. Antipruritic adjuncts (e.g., hydroxyzine 25 mg at night PRN) — for itch interfering with sleep; watch sedation.

15. Laxatives/stool softeners (e.g., PEG 17 g/day) — Purpose: manage opioid- or cholestyramine-related constipation; improves comfort and appetite.

---

Dietary Molecular “Supplements

Discuss with your clinician to avoid interactions. Focus is on digestion and nutrition.

1. MCT Oil (1–3 tbsp/day with meals): provides easily absorbed fat; bypasses pancreatic lipase; helps weight gain; may cause GI cramp if rushed.

2. Vitamin D3 (1,000–2,000 IU/day; higher if deficient under guidance): supports bone/immune function; fat-soluble—monitor levels.

3. Omega-3 (EPA/DHA 1–2 g/day): anti-inflammatory; may reduce pain perception; watch bleeding risk with anticoagulants.

4. Vitamin K (dose per labs): corrects deficiency from fat malabsorption; supports normal clotting.

5. Vitamin A (dose per labs; avoid excess): restores vision/skin/mucosa health if deficient.

6. Vitamin E (dose per labs): antioxidant; deficiency causes neuropathy/myopathy; avoid high-dose without indication.

7. Vitamin B12 (oral 1,000 mcg/day or periodic injection if low): supports nerve/blood health; deficiency common with malnutrition.

8. Pancreatic enzyme “add-on” acid buffer (e.g., sodium bicarbonate capsules when prescribed): may enhance PERT performance with low gastric pH; only with clinician advice.

9. Probiotics (standard CFU daily for 4–8 weeks): may reduce bloating/antibiotic-associated diarrhea; choose reputable brand.

10. Curcumin extract (standardized; follow label; avoid with anticoagulants): anti-inflammatory adjunct; evidence modest; use as culinary spice if unsure.

---

Immunity-booster / Regenerative / Stem-cell” Drugs

There are no approved immune-booster or stem-cell drugs to treat pancreatic adenoma itself. The safest evidence-based path is vaccination, nutrition, exercise, sleep, and managing comorbidities. Below are six items to clarify the landscape:

1. Vaccinations (flu, COVID-19, pneumococcal as indicated): protect from infections that can derail nutrition/recovery; no tumor effect.

2. Micronutrient repletion (A/D/E/K, B12, iron if low): fixes deficiency-related fatigue and poor healing; not anti-tumor.

3. No approved stem-cell therapy for pancreatic adenoma: any offers outside clinical trials should be avoided.

4. No approved “immune drugs” to shrink benign cysts: immune modulators are not indicated.

5. Clinical trials (surveillance tools/biomarkers): appropriate if offered by a reputable center; dosing is protocol-based.

6. Celiac plexus block/neurolysis (procedure, not a drug): for uncontrolled pain; reduces opioid need; does not treat the lesion.

---

Surgeries

1. Enucleation: shelling out a small, well-circumscribed lesion away from the main duct. Why: symptom relief with minimal pancreas loss.

2. Distal pancreatectomy (± spleen) for body/tail lesions: removes the tumor with a margin. Why: for MCN, SPN, or enlarging/at-risk cysts.

3. Pancreaticoduodenectomy (Whipple) for head lesions: removes head of pancreas plus duodenum/bile duct segment. Why: obstruction, main-duct IPMN, high-risk features.

4. Central pancreatectomy: removes a mid-gland tumor, preserving head and tail; Why: select benign lesions to preserve function.

5. Minimally invasive (laparoscopic/robotic) approaches: same operations via small cuts. Why: less pain, quicker recovery when feasible.

---

Prevention & Risk-Reduction Tips

1. Don’t smoke; if you do, get help to quit.

2. Limit alcohol; avoid binges that inflame the pancreas.

3. Maintain healthy weight with balanced meals and activity.

4. Choose whole foods; cut ultra-processed, sugary beverages.

5. Small, frequent meals if you get fullness/nausea.

6. Hydrate regularly; aim pale-yellow urine.

7. Regular checkups if you have a cyst already—keep MRI/EUS appointments.

8. Manage diabetes carefully to protect pancreas and nerves.

9. Follow enzyme and vitamin plans if prescribed.

10. Vaccinate per age/condition to avoid setbacks from infections.

---

When to See a Doctor Urgently

• New yellow eyes/skin, very dark urine, or pale stools.

• Fever, chills, or severe abdominal pain that won’t settle.

• Vomiting that stops you keeping fluids down.

• Unintentional weight loss or worsening weakness.

• New or worsening diabetes symptoms (thirst, frequent urination).

• Any rapid change in known cyst size/symptoms or missed surveillance.

---

What to Eat — and What to Avoid

1. Eat: soft, small, frequent meals—easier to tolerate.

2. Eat: lean protein (fish, poultry, eggs, tofu) to maintain muscle.

3. Eat: complex carbs (oats, brown rice, lentils) for steady energy.

4. Eat: healthy fats in modest portions (olive oil, avocado; consider MCT if advised).

5. Eat: cooked vegetables and ripe fruits to reduce bloating.

6. With meals, take PERT exactly as prescribed to digest fats.

7. Avoid: heavy, greasy/fried meals that trigger steatorrhea.

8. Avoid: large meals late at night—can worsen pain/nausea.

9. Avoid: alcohol—irritates the pancreas.

10. Avoid or limit: very spicy or acidic foods if they trigger symptoms.

---

Frequently Asked Questions

1. Can a pancreatic adenoma turn into cancer?
   Some types (e.g., MCN, certain IPMN) can progress over time. Serous cystadenoma rarely does. That’s why accurate typing and surveillance matter.

2. If mine is small and I feel fine, do I need surgery?
   Often no. Many small, low-risk cysts are watched with MRI/EUS at intervals.

3. How often will I need scans?
   Depends on size, features, and type; commonly every 6–24 months for low-risk lesions (your team sets the schedule).

4. Will enzymes help my pain?
   Enzymes help digestion and stools. They don’t directly treat pain but can reduce post-meal discomfort if fat malabsorption is present.

5. Are blood tests enough to tell if it’s safe?
   No. Imaging and, when needed, EUS with cyst-fluid tests guide decisions.

6. Is jaundice dangerous?
   Yes—it signals bile duct blockage. Call your doctor; sometimes urgent evaluation or stenting is needed.

7. Can diet shrink a cyst?
   Diet won’t shrink a cyst, but it can reduce symptoms, maintain weight, and help surgical recovery.

8. Are supplements necessary?
   Only if you’re deficient or symptomatic. Your clinician may check vitamin A/D/E/K, B12, and prescribe what you need.

9. What if I’m losing weight?
   See a dietitian early; consider PERT, small frequent meals, MCT oil, and correction of vitamin deficits.

10. Is keyhole (laparoscopic/robotic) surgery safe?
    For suitable cases and experienced teams, it can mean less pain and faster recovery with similar outcomes.

11. Could it come back after removal?
    If fully removed and benign, recurrence is uncommon, but follow the plan your surgeon gives you.

12. Does stress make symptoms worse?
    Stress can amplify pain and nausea. Mind-body strategies (breathing, mindfulness) often help.

13. Are there medicines that shrink the cyst?
    No established medicines reliably shrink benign pancreatic cysts. Management is watchful waiting or surgery when indicated.

14. Can I exercise?
    Yes—gentle, regular activity is encouraged. Avoid heavy straining during flares or early post-op.

15. Should I seek a second opinion?
    Yes, especially if surgery is proposed or the type is unclear. Pancreas centers can review imaging and pathology.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 08, 2025.

PDF Documents For This Disease Condition References